Clinical Trial Update: A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107 [Phase 1]

View source ↗

Summary

Phase 1 single-dose study in healthy volunteers to evaluate the safety, tolerability, and pharmacokinetics of STX107; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• STX107

Snippet

Sponsor: Seaside Therapeutics, Inc. | Conditions: Fragile X Syndrome | Phase 1 | Status: COMPLETED